Tuberculosis treatment in HIV infected ugandans with CD4 counts >350 cells/mm3 reduces immune activation with no effect on HIV load or CD4 count

C. Scott Mahan, Maria Walusimbi, Denise F. Johnson, Christina Lancioni, Edwin Charlebois, Joyce Baseke, Keith A. Chervenak, Roy D. Mugerwa, Diane V. Havlir, Harriet Mayanja-Kizza, Christopher C. Whalen, W. Henry Boom

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Both HIV and TB cause a state of heightened immune activation. Immune activation in HIV is associated with progression to AIDS. Prior studies, focusing on persons with advanced HIV, have shown no decline in markers of cellular activation in response to TB therapy alone. Methodology: This prospective cohort study, composed of participants within a larger phase 3 open-label randomized controlled clinical trial, measured the impact of TB treatment on immune activation in persons with non-advanced HIV infection (CD4>350 cells/mm3) and pulmonary TB. HIV load, CD4 count, and markers of immune activation (CD38 and HLADR on CD4 and CD8 T cells) were measured prior to starting, during, and for 6 months after completion of standard 6 month anti-tuberculosis (TB) therapy in 38 HIV infected Ugandans with smear and culture confirmed pulmonary TB. Results: Expression of CD38, and co-expression of CD38 and HLA-DR, on CD8 cells declined significantly within 3 months of starting standard TB therapy in the absence of anti-retroviral therapy, and remained suppressed for 6 months after completion of therapy. In contrast, HIV load and CD4 count remained unchanged throughout the study period. Conclusion:TB therapy leads to measurable decreases in immune activation in persons with HIV/TB co-infection and CD4 counts >350 cells/mm3.

Original languageEnglish (US)
Article numbere9138
JournalPLoS One
Volume5
Issue number2
DOIs
StatePublished - Feb 22 2010
Externally publishedYes

Fingerprint

CD4 Lymphocyte Count
tuberculosis
Tuberculosis
Chemical activation
HIV
therapeutics
cells
Pulmonary Tuberculosis
Therapeutics
T-cells
HLA-DR Antigens
lungs
Labels
Coinfection
randomized clinical trials
HIV Infections
HIV infections
Acquired Immunodeficiency Syndrome
Cohort Studies
Randomized Controlled Trials

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Tuberculosis treatment in HIV infected ugandans with CD4 counts >350 cells/mm3 reduces immune activation with no effect on HIV load or CD4 count. / Mahan, C. Scott; Walusimbi, Maria; Johnson, Denise F.; Lancioni, Christina; Charlebois, Edwin; Baseke, Joyce; Chervenak, Keith A.; Mugerwa, Roy D.; Havlir, Diane V.; Mayanja-Kizza, Harriet; Whalen, Christopher C.; Boom, W. Henry.

In: PLoS One, Vol. 5, No. 2, e9138, 22.02.2010.

Research output: Contribution to journalArticle

Mahan, CS, Walusimbi, M, Johnson, DF, Lancioni, C, Charlebois, E, Baseke, J, Chervenak, KA, Mugerwa, RD, Havlir, DV, Mayanja-Kizza, H, Whalen, CC & Boom, WH 2010, 'Tuberculosis treatment in HIV infected ugandans with CD4 counts >350 cells/mm3 reduces immune activation with no effect on HIV load or CD4 count', PLoS One, vol. 5, no. 2, e9138. https://doi.org/10.1371/journal.pone.0009138
Mahan, C. Scott ; Walusimbi, Maria ; Johnson, Denise F. ; Lancioni, Christina ; Charlebois, Edwin ; Baseke, Joyce ; Chervenak, Keith A. ; Mugerwa, Roy D. ; Havlir, Diane V. ; Mayanja-Kizza, Harriet ; Whalen, Christopher C. ; Boom, W. Henry. / Tuberculosis treatment in HIV infected ugandans with CD4 counts >350 cells/mm3 reduces immune activation with no effect on HIV load or CD4 count. In: PLoS One. 2010 ; Vol. 5, No. 2.
@article{b0a4a13a0c924748954e8a597c94ac77,
title = "Tuberculosis treatment in HIV infected ugandans with CD4 counts >350 cells/mm3 reduces immune activation with no effect on HIV load or CD4 count",
abstract = "Background: Both HIV and TB cause a state of heightened immune activation. Immune activation in HIV is associated with progression to AIDS. Prior studies, focusing on persons with advanced HIV, have shown no decline in markers of cellular activation in response to TB therapy alone. Methodology: This prospective cohort study, composed of participants within a larger phase 3 open-label randomized controlled clinical trial, measured the impact of TB treatment on immune activation in persons with non-advanced HIV infection (CD4>350 cells/mm3) and pulmonary TB. HIV load, CD4 count, and markers of immune activation (CD38 and HLADR on CD4 and CD8 T cells) were measured prior to starting, during, and for 6 months after completion of standard 6 month anti-tuberculosis (TB) therapy in 38 HIV infected Ugandans with smear and culture confirmed pulmonary TB. Results: Expression of CD38, and co-expression of CD38 and HLA-DR, on CD8 cells declined significantly within 3 months of starting standard TB therapy in the absence of anti-retroviral therapy, and remained suppressed for 6 months after completion of therapy. In contrast, HIV load and CD4 count remained unchanged throughout the study period. Conclusion:TB therapy leads to measurable decreases in immune activation in persons with HIV/TB co-infection and CD4 counts >350 cells/mm3.",
author = "Mahan, {C. Scott} and Maria Walusimbi and Johnson, {Denise F.} and Christina Lancioni and Edwin Charlebois and Joyce Baseke and Chervenak, {Keith A.} and Mugerwa, {Roy D.} and Havlir, {Diane V.} and Harriet Mayanja-Kizza and Whalen, {Christopher C.} and Boom, {W. Henry}",
year = "2010",
month = "2",
day = "22",
doi = "10.1371/journal.pone.0009138",
language = "English (US)",
volume = "5",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Tuberculosis treatment in HIV infected ugandans with CD4 counts >350 cells/mm3 reduces immune activation with no effect on HIV load or CD4 count

AU - Mahan, C. Scott

AU - Walusimbi, Maria

AU - Johnson, Denise F.

AU - Lancioni, Christina

AU - Charlebois, Edwin

AU - Baseke, Joyce

AU - Chervenak, Keith A.

AU - Mugerwa, Roy D.

AU - Havlir, Diane V.

AU - Mayanja-Kizza, Harriet

AU - Whalen, Christopher C.

AU - Boom, W. Henry

PY - 2010/2/22

Y1 - 2010/2/22

N2 - Background: Both HIV and TB cause a state of heightened immune activation. Immune activation in HIV is associated with progression to AIDS. Prior studies, focusing on persons with advanced HIV, have shown no decline in markers of cellular activation in response to TB therapy alone. Methodology: This prospective cohort study, composed of participants within a larger phase 3 open-label randomized controlled clinical trial, measured the impact of TB treatment on immune activation in persons with non-advanced HIV infection (CD4>350 cells/mm3) and pulmonary TB. HIV load, CD4 count, and markers of immune activation (CD38 and HLADR on CD4 and CD8 T cells) were measured prior to starting, during, and for 6 months after completion of standard 6 month anti-tuberculosis (TB) therapy in 38 HIV infected Ugandans with smear and culture confirmed pulmonary TB. Results: Expression of CD38, and co-expression of CD38 and HLA-DR, on CD8 cells declined significantly within 3 months of starting standard TB therapy in the absence of anti-retroviral therapy, and remained suppressed for 6 months after completion of therapy. In contrast, HIV load and CD4 count remained unchanged throughout the study period. Conclusion:TB therapy leads to measurable decreases in immune activation in persons with HIV/TB co-infection and CD4 counts >350 cells/mm3.

AB - Background: Both HIV and TB cause a state of heightened immune activation. Immune activation in HIV is associated with progression to AIDS. Prior studies, focusing on persons with advanced HIV, have shown no decline in markers of cellular activation in response to TB therapy alone. Methodology: This prospective cohort study, composed of participants within a larger phase 3 open-label randomized controlled clinical trial, measured the impact of TB treatment on immune activation in persons with non-advanced HIV infection (CD4>350 cells/mm3) and pulmonary TB. HIV load, CD4 count, and markers of immune activation (CD38 and HLADR on CD4 and CD8 T cells) were measured prior to starting, during, and for 6 months after completion of standard 6 month anti-tuberculosis (TB) therapy in 38 HIV infected Ugandans with smear and culture confirmed pulmonary TB. Results: Expression of CD38, and co-expression of CD38 and HLA-DR, on CD8 cells declined significantly within 3 months of starting standard TB therapy in the absence of anti-retroviral therapy, and remained suppressed for 6 months after completion of therapy. In contrast, HIV load and CD4 count remained unchanged throughout the study period. Conclusion:TB therapy leads to measurable decreases in immune activation in persons with HIV/TB co-infection and CD4 counts >350 cells/mm3.

UR - http://www.scopus.com/inward/record.url?scp=77949590071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949590071&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0009138

DO - 10.1371/journal.pone.0009138

M3 - Article

C2 - 20179751

AN - SCOPUS:77949590071

VL - 5

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e9138

ER -